Catalent’s Elpida Therapeutics deal shows why AAV manufacturing is still a strategic choke point
Ultra-rare gene therapies need more than science. Elpida’s Catalent deal tests whether AAV manufacturing can keep patients within reach.
Why AAVnerGene’s AAVone 2.1 could matter for next-generation gene therapy manufacturing
AAV gene therapy needs better economics. AAVnerGene’s AAVone 2.1 tests whether single-plasmid production can ease the scale-up squeeze.
What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy
Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.